CELLPATH HOLDINGS LIMITED

Credit Analysis: CELLPATH HOLDINGS LIMITED Prepared for: Internal Credit Committee Date: 2026-04-14 Analyst: Commercial Credit Analyst

1. Credit Opinion: DECLINE

Reasoning: This is a non-trading holding company with no operational cash flow, no turnover, and no current assets. The entire balance sheet consists of a single fixed asset (likely an investment in a subsidiary) funded by a liability (creditors due within one year). The company has zero liquidity and no demonstrable ability to service any new debt. The financial information is stale (last filed accounts are for 2016), and the company is currently filing as an "Audit Exemption Subsidiary," indicating it is part of a larger group. Lending to a non-trading entity with no cash flow and no assets beyond an intercompany investment presents unacceptable risk.

2. Financial Strength: Weak / No Standalone Capacity

• Balance Sheet Structure: The balance sheet is extremely simple and static. Total assets of £1.55m are entirely composed of "Fixed assets," which are almost certainly investments in subsidiary undertakings. There are zero current assets (no cash, no debtors, no stock).
• Leverage: The company has current liabilities of £273k, creating negative working capital (Net Current Liabilities: -£273k). This means the company's short-term debts exceed its liquid assets by the full amount. It is reliant on the parent company or directors to meet these obligations.
• Net Assets: Net assets of £1.28m represent the historical cost of the investment less the liability. This provides no tangible security for a lender unless a charge is taken over the shares of the subsidiary, which is complex and offers secondary recovery at best.
• Filing Status: The company is classified as an "Audit Exemption Subsidiary." This confirms it is not the top-level parent and is likely consolidated into a larger group. The group's financial health is the critical factor, not this entity's standalone position.

3. Cash Flow Assessment: None / Negative

• Operating Cash Flow: The accounts text explicitly states the company has "never traded." There is no profit and loss account, no turnover, and no operating income. The company generates zero cash from operations.
• Liquidity: With no current assets, the company has zero liquidity. It cannot pay a £1 invoice without a capital injection from its shareholders or the group.
• Working Capital: Working capital is deeply negative. The company is technically insolvent on a liquidity basis, relying entirely on the forbearance of its creditors (likely the parent/directors).
• Dividend / Income Potential: The only potential cash inflow would be dividends from its subsidiary. However, there is no evidence of this in the filed accounts. The static net asset position suggests no dividends have been received or retained.

4. Monitoring Points (If Facility Were to Be Considered)

If the credit request were for a group facility where this entity is a minor holding company, the following would be essential:

1. Group Accounts: Immediate requirement for the latest consolidated accounts of the ultimate parent undertaking. This entity's creditworthiness is entirely derived from the group.
2. Subsidiary Performance: Full financials and a management account pack for the trading subsidiary (likely the entity behind the "CellPath" brand) to assess true operating cash flow and profitability.
3. Intercompany Position: A detailed breakdown of the £273k creditor. Is it owed to the parent, a director, or a third party? Is it subordinated?
4. Current Filing Status: The 2016 accounts are critically stale. The bank must obtain the most recent management accounts and confirm the company's current financial position and compliance with filing requirements.
5. Purpose of Facility: A clear and justifiable business purpose for lending through a non-trading holding company must be provided. Lending for working capital or general corporate purposes to this entity is not viable.